SCHEMBL5217154

SCHEMBL5217154

CN(c1ncccc1CNc1nc(Nc2ccc3c(c2)CCC(=O)N3)ncc1C(F)(F)F)S(C)(=O)=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTK2 Q05397 19/20 1.00
PTK2B Q14289 9/20 1.00
AURKA O14965 2/20 0.88
CDK1 P06493 2/20 0.88
CDK7 P50613 2/20 0.88
PLK4 O00444 1/20 0.88
PDPK1 O15530 1/20 0.88
DAPK3 O43293 1/20 0.88
JAK2 O60674 1/20 0.88
ROCK2 O75116 1/20 0.88
STK16 O75716 1/20 0.88
PRKD3 O94806 1/20 0.88
MAP4K4 O95819 1/20 0.88
PAK4 O96013 1/20 0.88
CHEK2 O96017 1/20 0.88
NTRK1 P04629 1/20 0.88
PRKCG P05129 1/20 0.88
INSR P06213 1/20 0.88
LCK P06239 1/20 0.88
FYN P06241 1/20 0.88

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5210663 0.94 PTK2 (0.89) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL29637167 0.94 PTK2 (1.00) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL1206959 0.94 PTK2 (1.00) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL29381854 0.94 PTK2 (1.00) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL21062022 0.93 PTK2 (0.99) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL29496512 0.93 PTK2 (0.99) PTK2PTK2BAURKACDK1CDK7
SCHEMBL19203861 0.91 PTK2 (0.83) PTK2PTK2BAURKACDK1CDK7
SCHEMBL5212542 0.90 PTK2 (0.88) PTK2PTK2BAURKACDK1CDK7
SCHEMBL5185817 0.89 PTK2 (0.89) PTK2PTK2BAURKACDK1CDK7
Pf-00562271 SCHEMBL20471937 0.88 PTK2 (1.00) PTK2PTK2BAURKACDK1CDK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 US claimed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 EP claimed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 WO claimed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 US claimed
US-7235562-B2 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC (US) 2007-06-26 US disclosed
EP-1758887-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH Pfizer Products Incorporated (US) 2007-03-07 EP disclosed
WO-2005111016-A1 PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH PFIZER PRODUCTS INC. (US) 2005-11-24 WO disclosed
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth PFIZER INC 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050256111-A1 Pyrimidine derivatives for the treatment of abnormal cell growth TYMS, TYMP, CCNA1 PTK2 3610/4885PTK2B 3168/4885AURKA 313/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.